Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Celcuity
Start Date
December 20, 2022
End Date
December 31, 2029
Administered By
Duke Cancer Institute
Awarded By
Celcuity
Start Date
December 20, 2022
End Date
December 31, 2029